Back to Authors

Zhang, Hui

https://orcid.org/0000-0001-6787-7403

Mayo Clinic

Blueprint Medicines (United States)

Citations 1

Plasma-Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States
Pignolo, Robert J. , McCarrick-Walmsley, Ruth, Qiu, Shirley , Hunter, Jeffrey W. , Barr, Sharon, Zhang, Hui , Wang, Haitao , Qiu, Shirley, He, Kevin , Kaplan, Frederick S.

Journal of Bone and Mineral Research | December 26, 2021 | Volume: 37 | Issue: 3 | Pages: 475-483

10.1002/jbmr.4492 Get It

ABSTRACT Fibrodysplasia ossificans progressiva (FOP) is a progressive, debilitating genetic disease in which skeletal muscle and connective tissue is episodically replaced by heterotopic bone. Discovery of surrogate biomarkers of disease (genotype)-related and flare-up-associated activity of FOP in a readily accessible matrix, such as plasma, would facilitate an understanding of the complex pathophysiology of FOP, aid patient care, and provide a valuable tool for the development and monitoring of potential therapeutics. In a case–control study, using a carefully collected and curated set of plasma samples from 40 FOP patients with the classic ACVR1R206H mutation and 40 age- and sex-matched controls, we report the identification of disease-related and flare-up-associated biomarkers of FOP using a multiplex analysis of 113 plasma-soluble analytes. Adiponectin (implicated in hypoxia, inflammation, and heterotopic ossification) as well as tenascin-C (an endogenous activator of innate immune signaling through the TLR4 pathway and a substrate for kallikrein-7) were highly correlated with FOP genotype, while kallikrein-7 was highly correlated with acute flare-up status. Plasma-soluble biomarkers for FOP support a flare-up-related acute inflammatory phase of disease activity superimposed on a genotypic background of chronic inflammation. © 2021 American Society for Bone and Mineral Research (ASBMR).